PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report

Joan Manel Gasent Blesa a  Miguel Peris Godoy b
María Fonfría Esparcia a  Sara Blasco Mollá a
Balbino Mancheño Magán c  José Miguel Sempere Ortells d
José Luis Sánchez e

Departamentos de a Oncología Médica y b Medicina Interna, Hospital de Dénia, Marina Salud, Dénia, Departamentos de c Química Orgánica y d Inmunología, Universidad de Alicante, Alicante, y e Departamento de Ética, Universidad Católica de València, València, España

Key Words
Hormone-resistant prostate cancer · Prostate serum antigen · Lenalidomide

Abstract
Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalidomide in HRPC. In this paper, we report that lenalidomide showed antitumoral activity in a patient with HRPC and bone metastases pre-treated with chemotherapy, decreased the PSA level and improved the patient’s health status for the first 5 months. It is important to emphasize that it was not associated with hematologic toxicity.

Introduction
Prostate cancer is the most common cancer and the second leading cause of cancer death in men [1]. Androgen deprivation therapy is the treatment of choice in patients with advanced metastatic disease, although progression typically occurs within 1–2
years of initial response [2, 3]. Secondary hormonal therapy is an option in some patients; however, most neoplasms ultimately progress to a situation of androgen-independent growth, namely hormone-resistant prostate cancer (HRPC), androgen-independent prostate cancer or, recently, castration-resistant prostate cancer.

Clinical manifestations include rising PSA (prostate serum antigen) concentration, bone metastases, substantive pain, and soft-tissue/lymph node metastases [4]. Some forms of HRPC treatment are systemic radiation therapy, chemotherapy, immunotherapy and estrogen therapy. However, outcomes in HRPC are very poor and therefore novel agents are needed to improve the treatment of this condition. Many approaches, such as drugs that target specific pathways involved in cell signaling, proliferation, apoptosis, immune modulation and angiogenesis, are currently under investigation to improve survival benefit.

Lenalidomide is a thalidomide analog and also known as a member of the so-called immunomodulatory drugs (I\!\!M\!\!Ds) with immunomodulatory and antiangiogenic properties. In preclinical studies, lenalidomide demonstrated antitumoral activity, inhibiting hypoxia-induced factor-1α expression by endothelial cells and epithelial tumor cells, including prostate cells [5], and an increase in PC-3 prostate cancer cell apoptosis with monotherapy or in combination with docetaxel [6]. Using in vitro and in vivo models of prostate cancer, lenalidomide inhibited growth factor-induced invasion and produced synergistic effects in combination with docetaxel that slowed tumor progression [7]. The few published reports about the use of lenalidomide alone or in combination in HRPC patients [8–17] show clear evidence of its clinical antitumoral activity in this disease. In this paper, we demonstrate that lenalidomide not only has antitumoral activity but also has no associated hematologic toxicity.

**Case Report**

In this paper, we discuss the case of a 65-year-old male patient diagnosed in August 1999, by transurethral resection of the prostate, with a Gleason 6/10 prostate adenocarcinoma. His past medical history included renal clear cell adenocarcinoma of both kidneys and constipation treated with lactulose. The serum PSA at the time of diagnosis was elevated to 19.7 ng/ml (normal range 0.0–4.0). Radiotherapy and combined androgen blockade (CAB) therapy was initiated, comprising lutein-releasing hormone analog (Zoladex) and bicalutamide 50 mg daily (table 1). The patient remained asymptomatic with a low PSA level for 5 years (PSA nadir 0.1 ng/ml). In January 2008, biochemical and bone progression was diagnosed with an increased PSA of 12 ng/ml; bone metastases were detected by bone and CT scans. A similar scheme of hormonal therapy with CAB was administered. The patient was at castration testosterone levels (<50 ng/ml). However, 3 months later, his PSA rose again to 37 ng/ml.

In April 2008, the patient was referred to our department with HRPC with bone-only metastases. The patient received a third hormonal therapy with cyproterone acetate for 2 months, but biochemical progression was detected with a new increase of PSA to 64 ng/ml. Subsequently, docetaxel-prednisone-based chemotherapy was started, but the patient’s PSA level rose again after an initial drop (64–12–38–57 ng/ml); bone and CT scans showed bone-only metastases. In October, second-line chemotherapy with oxaliplatin and capecitabine on a compassionate-use basis was administered, but after 3 cycles of treatment, PSA level was 233 ng/ml. In November 2008, this therapy was replaced by treatment with fulvestran for compassionate use and, after the first month, PSA level returned to 32 ng/ml. However, in March 2009, his PSA value was higher than 300 ng/ml. Sunitinib was proposed for compassionate use. After being treated for 5 months with sunitinib (50 mg daily on days 1–4, given every 42 days), serum PSA level rose to 749 ng/ml. Soon thereafter, in August 2009, the patient began treatment with vinblastine-Adriamycin-estramustine and ketoconazole,
which was discontinued after the third cycle given the clinical deterioration associated with more intense pain (initial PS 1; final PS 2) and increased levels of serum PSA (1,146 ng/ml). In October, the patient received antalgic radiotherapy for bone metastases.

A new line of treatment with lenalidomide 25 mg/day for compassionate use together with analgesic agents was administered in November 2009. Concomitant analgesic medication for bone pain consisted of ibuprofen 600 mg/8 h, morphine sulfate 10 mg for rescue and fentanyl patches that were discontinued in January 2010. Hematological toxicity was assessed every 2 weeks and PSA monthly. The patient responded well to lenalidomide therapy, PSA level markedly declined to 391 ng/ml and no hematological or cutaneous adverse events were documented; similar hemoglobin levels were maintained before and after lenalidomide treatment (10.4–11.7 g/dl). The patient regained the ability to walk over 7 km daily, maintaining his lifestyle, and he improved his general performance status until April 2010, when fentanyl patches were reintroduced and his PSA level rose to 422 ng/ml. In May 2010, an increased PSA level of 893 ng/ml was accompanied by clinical worsening due to the evolution of the disease, and therapy was suspended.

After that, Estracyt (estramustine) 140 mg/12 h was started but no response was obtained; PSA level in July 2010 was >5,000 ng/ml, and bone and CT scans revealed lymph node, liver and lung metastases. The progressive deterioration of the patient’s health led to hospital admission and death in October 2010.

Discussion

Proliferation, angiogenesis and evasion of immune surveillance are important pathways by which HRPC progresses. Based on antiangiogenic and antitumoral properties of IMiDs, we may highlight thalidomide and lenalidomide among the new agents used for treating HRCP. It has been described that lenalidomide inhibits tumor necrosis factor-α production, diminishes levels of VEGF and basic fibroblast growth factor, stimulates T cells and hinders angiogenesis. It also promotes apoptosis in malignant cells. The antitumoral activity of lenalidomide is approximately 5,000 times more potent than thalidomide in animal models, and, furthermore, it has the additional advantage of being associated with a better toxicity profile.

In fact, preliminary studies suggest that lenalidomide may have clinical activity in patients with metastatic castration-resistant prostate cancer [16, 17]. Nevertheless, published data about the use of lenalidomide in HRPC are rare so far, particularly in chemotherapy pre-treated patients. All of the data have shown clear evidence of antitumor activity of lenalidomide alone [13, 14] or in combination with docetaxel [9, 12], paclitaxel [10, 15], ketoconazole [11] or GM-CSF [8] in metastatic HRPC patients. Responses described in these studies are promising with regard to survival advantage.

According to our experience, the patient described here, pre-treated with chemotherapy, showed favorable response to lenalidomide therapy for 5 months – improving his general health status and quality of life, even discontinuing fentanyl administration for 4 months. It is significant to note that PSA levels declined, and disease response and pain reduction during lenalidomide administration was not accompanied by any toxicity. Hematological tests did not show alteration in hemoglobin levels, and the patient did not experience cutaneous adverse effects. This observation provides an additional benefit and suggests that lenalidomide may be an attractive drug because of its antineoplastic activity and low side effect profile. The evolution of the disease with the appearance of metastases led to worsening of the clinical situation of the patient.
The prognosis of prostate cancer is mainly determined by the presence or absence of metastases [18]. In our patient, the development of bone, lymph node, liver and lung metastases led to progressive deterioration, which is a common complication due to widespread disease expansion.

Other treatments received by the patient mainly included subsequent lines of hormonal therapy, radiotherapy and chemotherapy with antineoplastic agents – standard treatments in the management of HRPC. Although reductions in PSA levels were achieved for a limited period of time, successive changes of therapy were required because of relapse and disease progression.

Given the need for new agents that do not bear a potentially high cost in terms of side effects in the management of HRPC patients, lenalidomide is proposed as an interesting option.

**Conclusion**

In conclusion, the present case report presents new evidence of the potential of lenalidomide to provide clinical benefits to HRPC patients because of its antitumoral activity and lack of toxicity; the use of lenalidomide is supported in this patient population for delaying disease progression.
Table 1. Treatment and response

<table>
<thead>
<tr>
<th>Date</th>
<th>Prostate cancer treatment</th>
<th>Initial PSA ng/ml</th>
<th>Final PSA ng/ml</th>
<th>Clinical observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aug/99–Jan/08</td>
<td>RT/CAB</td>
<td>19.7</td>
<td>12</td>
<td>PSA nadir 0.1 ng/ml Bone metastases (CT)</td>
</tr>
<tr>
<td>Jan/08–Apr/08</td>
<td>CAB</td>
<td>12</td>
<td>37</td>
<td>Castration testosterone levels</td>
</tr>
<tr>
<td>Apr/08–Jun/08</td>
<td>Androcur</td>
<td>37</td>
<td>64</td>
<td>Bone metastases (CT)</td>
</tr>
<tr>
<td>Jun/08–Aug/08</td>
<td>Taxotere/Pred</td>
<td>64</td>
<td>57</td>
<td>Bone metastases (CT)</td>
</tr>
<tr>
<td>Oct/08–Nov/08</td>
<td>Oxi/Cap</td>
<td>57</td>
<td>233</td>
<td></td>
</tr>
<tr>
<td>Nov/08–Mar/09</td>
<td>Fulvestrant</td>
<td>203</td>
<td>321</td>
<td>Bone metastases (CT)</td>
</tr>
<tr>
<td>Mar/09–Aug/09</td>
<td>Sunitinib</td>
<td>321</td>
<td>749</td>
<td></td>
</tr>
<tr>
<td>Aug/09–Sep/09</td>
<td>Vin/adri/estra/keto</td>
<td>749</td>
<td>1,146</td>
<td>Clinical deterioration Intense pain (final PS 2)</td>
</tr>
<tr>
<td>Oct/09</td>
<td>Antalgiec RT</td>
<td></td>
<td></td>
<td>Bone metastases (CT)</td>
</tr>
<tr>
<td>Nov/09–May/10</td>
<td>Lenalidomide</td>
<td>1,146</td>
<td>893</td>
<td>Clinical improvement No hematologic toxicity</td>
</tr>
<tr>
<td>May/10–Jul/10</td>
<td>Estracyt</td>
<td>1,146</td>
<td>&gt;5,000</td>
<td>No response</td>
</tr>
<tr>
<td>Oct/10</td>
<td></td>
<td></td>
<td></td>
<td>Lymph node, liver and lung metastases</td>
</tr>
</tbody>
</table>

RT = Radiation therapy; CAB = combined androgen blockade therapy; Pred = prednisone; Oxi = oxaliplatin; Cap = capecitabine; Vin/adri/estra/keto = vinblaste-adriamycin-estramustine-ketoconazole.

References


